[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Mirador Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100601671","phase-2-a-phase-2-study-to-evaluate-therapies-for-inflammatory-bowel-disease-100601671",false,"NCT07113522","A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease","A Phase 2, Multi-Center, Platform Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics With Multiple Therapies in Participants With Active Crohn's Disease or Active Ulcerative Colitis (ASCEND-IBD)","ASCEND-IBD","Inclusion Criteria-Crohn's Disease:\n\n* Diagnosis of Crohn's Disease (CD), as confirmed by endoscopy and histopathology\n* Moderately to severely active CD as defined by Clinical Disease Activity Index (CDAI) and Simple Endoscopic Score (SES-CD)\n* Meets drug stabilization requirements\n\nInclusion Criteria-Ulcerative Colitis:\n\n* Diagnosis of Ulcerative Colitis (UC), as confirmed by endoscopy and histopathology\n* Moderately to severely active UC as defined by a 3-component MMCS\n* Meets drug stabilization requirements\n\nExclusion Criteria-Crohn's Disease:\n\n* Diagnosis of indeterminate colitis\n* Suspected or diagnosed intra-abdominal or perianal abscess at Screening\n* Previous small bowel resection with combined resected length of \\> 100 cm or previous colonic resection of \\> 2 segments\n* CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic and\u002For ileal involvement\n\nExclusion Criteria-Ulcerative Colitis:\n\n* Current evidence or within recent history (within last 6 months) of fulminant colitis, toxic megacolon, or bowel perforation\n* Current stoma or impending need for colostomy or ileostomy\n* Received IV corticosteroids within 14 days prior to Screening or during the Screening Phase\n* Previous total proctocolectomy or subtotal colectomy","ALL","18 Years","80 Years",{"count":21,"type":22},140,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.",[28,29,30],"Inflammatory Bowel Disease (IBD)","Ulcerative Colitis (UC)","Crohn's Disease",[32,15,33,34,35,30],"Inflammatory Bowel Diseases","Ulcerative Colitis","UC","CD","RECRUITING","2026-03-10",{"date":39,"type":40},"2026-03-12","ACTUAL",{"date":42,"type":40},"2025-06-26",{"date":44,"type":22},"2028-02-04",{"name":46,"class":47},"Mirador Therapeutics, Inc.","INDUSTRY",66,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":54,"conditions":63,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100625489","phase-1-a-first-in-human-single-and-multiple-ascending-dose-study-of-mt-251-100625489","NCT07423299","A First-in-Human Single and Multiple Ascending Dose Study of MT-251","A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Doses of MT-251 in Healthy Participants","Inclusion Criteria:\n\n1. Male or female participants between 19 and 55 years of age (inclusive) at the time of signing informed consent.\n2. Female participants must be of nonchildbearing potential, defined as postmenopausal or surgically sterile, and have official documentation, at least 6 months prior to the first dose.\n3. Male subjects must use highly effective forms of contraception during sexual intercourse with female partners of childbearing potential. A non-vasectomized, male subject must agree to use a condom with a chemical barrier method.\n4. Continuous non-smoker who has not used tobacco or nicotine-containing products for at least 3 months prior to the first dose of drug.\n5. Good general health.\n6. Able to provide written informed consent and understand and comply with the requirements of the study.\n\nExclusion Criteria:\n\n1. History or presence of any clinically significant organ system disease.\n2. Abnormal laboratory assessments, physical exam of ECG outside the normal range that is judged by the Investigator to be clinically significant.\n3. History of alcohol or drug abuse within the past 24 months.\n4. Current use or history of regular tobacco or nicotine-containing products within 3 months prior to screening.\n5. Administration of any prescription drug within 21 days or 5 half-lives (whichever is longer) of study drug administration; or over-the-counter drug within 7 days or 5 half-lives (whichever is longer) of study drug administration.\n6. Administration or use of any investigational drug or device within 30 days preceding the first does of study drug administration.\n7. Blood donation within 60 days prior to dosing or plasma donation within 14 days prior to dosing.\n8. Sensitivity to any of the study drugs, or components thereof, or drug or other allergy that in the opinion of the Investigator or Sponsor Medical Monitor, contraindicates participation in the study.",true,"19 Years","55 Years",{"count":60,"type":22},70,[62],"PHASE1",[64],"Healthy Volunteers",[66,67],"MT-251","Phase 1","2026-02-23",{"date":70,"type":40},"2026-02-25",{"date":72,"type":40},"2026-01-23",{"date":74,"type":22},"2027-03-08",{"name":46,"class":47},1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":56,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":76},"100609806","phase-1-a-first-in-human-single-and-multiple-ascending-dose-study-of-mt-201-100609806","NCT07219368","A First-in-Human Single and Multiple Ascending Dose Study of MT-201","A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Doses of MT-201 in Healthy Participants","Inclusion Criteria:\n\n1. Male participant or female participant of nonchildbearing potential between 19 and 55 years of age (inclusive) at the time of signing informed consent.\n2. Female participants must be of nonchildbearing potential, defined as postmenopausal or surgically sterile, and have official documentation, at least 6 months prior to the first dose.\n3. Male participants with female partners of childbearing potential who are involved in heterosexual intercourse or activities that could lead to pregnancy must use barrier method of contraception (male condom) and refrain from sperm donation.\n4. Good general health.\n5. Able to provide written informed consent and understand and comply with the requirements of the study.\n\nExclusion Criteria:\n\n1. History or presence of any clinically significant organ system disease.\n2. Abnormal laboratory assessments, physical exam of ECG outside the normal range that is judged by the Investigator to be clinically significant.\n3. History of alcohol or drug abuse within the past 24 months.\n4. Current use or history of regular tobacco, or nicotine-containing products within 3 months prior to screening.\n5. Administration or use of any investigational drug or device within 30 days preceding the first dose of study drug administration.\n6. Blood donation within 60 days prior to dosing or plasma donation within 14 days prior to dosing.",{"count":85,"type":22},72,[62],"First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-201 in healthy participants.",[89],"Healthy Volunteer",[91,67],"MT-201","2025-10-31",{"date":94,"type":40},"2025-11-04",{"date":96,"type":40},"2025-10-08",{"date":98,"type":22},"2026-12-31",{"name":46,"class":47},""]